The management of hyperuricemia and gout in patients with heart failure

European Journal of Heart Failure

Volumn 4, Issue 4, 2002, Pages 403-410

  Spieker, Lukas E ^a   Ruschitzka, Frank T ^a   Lüscher, Thomas F ^a   Noll, Georg ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ANGIOTENSIN RECEPTOR ANTAGONIST; ASCORBIC ACID; CALCITONIN; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CONTRAST MEDIUM; CYANOCOBALAMIN; CYCLOSPORIN; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ESTROGEN; ETHAMBUTOL; FENOFIBRATE; GLUCOCORTICOID; LEVODOPA; LOOP DIURETIC AGENT; LOSARTAN; NICOTINIC ACID; PARACETAMOL; PYRAZINAMIDE; SALICYLIC ACID; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TIENILIC ACID; TORASEMIDE; UNINDEXED DRUG; URICOSURIC AGENT; VERAPAMIL; ANTIGOUT AGENT; CARDIOVASCULAR AGENT; URIC ACID;

GASTROINTESTINAL TOXICITY; GOUT; HEART FAILURE; HUMAN; HYPERURICEMIA; LEUKOPENIA; LIVER TOXICITY; NEPHROTOXICITY; PRIORITY JOURNAL; REVIEW; THROMBOCYTOPENIA; URIC ACID BLOOD LEVEL; BLOOD; COMORBIDITY; CONGESTIVE HEART FAILURE; RISK FACTOR;

CARDIOVASCULAR AGENTS; COMORBIDITY; GOUT; GOUT SUPPRESSANTS; HEART FAILURE, CONGESTIVE; HUMANS; RISK FACTORS; URIC ACID;

EID: 0036675837     PISSN: 13889842     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1388-9842(02)00086-7     Document Type: Review

References (106)

1. Fox IH. Metabolic basis for disorders of purine nucleotide degradation. Metabolism 1981;30:616-34.
2. Roubenoff R, Klag MJ, Mead MA, Liang K-Y, Seidler AJ, Hochberg MC. Incidence and risk factors for gout in white men. J Am Med Assoc 1991;266:3004-7.
3. Emmerson BT. Alteration of urate metabolism by weight reduction. Aust N Z J Med 1973;3:410-2.
4. Facchini F, Chen Y-DI, Hollenbeck CB. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. J Am Med Assoc 1991;266:3008-11.
5. Kalemkerian GP, Darwish B, Varterasian ML. Tumor lysis syndrome in small cell carcinoma and other solid tumors. Am J Med 1997;103:363-7.
6. Hart LE, Egier BP, Shimizu AG, Tandan PJ, Sutton JR. Exertional heat stroke: the runner's nemesis. Can Med Assoc J 1980;122:1144-50.
7. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000;27:1501-5.
8. Paulus HE, Coutts A, Calabro JJ, Klinenberg JR. Clinical significance of hyperuricemia in routinely screened hospitalized men. J Am Med Assoc 1970;211:277-81.
9. Lip GY, Beevers M, Beevers DG. Serum urate is associated with baseline renal dysfunction but not survival or deterioration in renal function in malignant phase hypertension. J Hypertens 2000;18:97-101.
10. Fessel WJ. Renal outcomes of gout and hyperuricemia. Am J Med 1979;67:74-82.
11. Dini G, Bartolini M, Massimo L, et al. Early deaths in acute lymphoblastic leukemia (ALL): results of the Italian Pediatric Cooperative Group for Therapy of Acute Leukemia (AILAIEOP). Med Pediatr Oncol 1984;12:189-93.
12. Smalley RV, Guaspari A, Haase-Statz S, Anderson SA, Cederberg D, Hohneker JA. Allopurinol: intravenous use for prevention and treatment of hyperuricemia. J Clin Oncol 2000;18:1758-63.
13. Teerlink JR, Goldhaber SZ, Pfeffer MA. An overview of contemporary etiologies of congestive heart failure. Am Heart J 1991;121:1852-3.
14. Myers AR, Epstein FH, Dodge HJ, Mikkelsen WM. The relationship of serum uric acid to risk factors in coronary heart disease. Am J Med 1968;45:520-8.
15. Tofuku Y, Kuroda M, Takeda R. Hyperuricemia associated with hypertension. A 4-year follow-up study of hyperuricemic hypertensives. Jpn Circ J 1978;42:871-9.
16. Fessel WJ. High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 1980;68:401-4.
17. Gelber AC, Klag MJ, Mead LA, et al. Gout and risk for subsequent coronary heart disease. The Meharry-Hopkins Study. Arch Intern Med 1997;157:1436-40.
18. Schmidt MI, Watson RL, Duncan BB, et al. Clustering of dyslipidemia, hyperuricemia, diabetes, and hypertension and its association with fasting insulin and central and overall obesity in a general population. Atherosclerosis Risk in Communities Study Investigators. Metabolism 1996;45:699-706.
19. Culleton BF, Larson MG, Kannel WB, Levy D. Serum uric acid and risk for cardiovascular disease and death: the Framingham Heart Study. Ann Intern Med 1999;131:7-13.
20. Thomas RD, Newill A, Morgan DB. The cause of the raised plasma urea of acute heart failure. Postgrad Med J 1979;55:10-4.
21. Hoeper MM, Hohlfeld JM, Fabel H. Hyperuricaemia in patients with right or left heart failure. Eur Respir J 1999;13:682-5.
22. Leyva F, Anker S, Swan JW, et al. Serum uric acid as an index of impaired oxidative metabolism in chronic heart failure. Eur Heart J 1997;18:858-65.
23. Leyva F, Anker SD, Godsland IF, et al. Uric acid in chronic heart failure: a marker of chronic inflammation. Eur Heart J 1998;19:1814-22.
24. Grum CM, Ketai LH, Myers CL, Shlafer M. Purine efflux after cardiac ischemia: relevance to allopurinol cardioprotection. Am J Physiol 1987;252:H368-H373.
25. Anker SD, Leyva F, Poole-Wilson PA, Kox WJ, Stevenson JC, Coats AJ. Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure. Heart 1997;78:39-43.
26. Bettencourt P, Ferreira A, Dias P, et al. Predictors of prognosis in patients with stable mild to moderate heart failure. J Card Fail 2000;6:306-13.
27. Bigger JT, Heller CA, Wenger TL, Weld FM. Risk stratification after acute myocardial infarction. Am J Cardiol 1978;42:202-10.
28. Dearth JC, Tompkins RB, Giuliani ER, Feldt RH. Hyperuricemia in congenital heart disease. Am J Dis Child 1978;132:900-20.
29. Ellis EN, Brouhard BH, Conti VR. Renal function in children undergoing cardiac operations. Ann Thorac Surg 1983;36:167-72.
30. Nagaya N, Uematsu M, Satoh T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med 1999;160:487-92.
31. Voelkel MA, Wynne KM, Badesch DB, Groves BM, Voelkel NE Hyperuricemia in severe pulmonary hypertension. Chest 2000;117:19-24.
32. Langford HG, Blaufox MD, Borhani NO, et al. Is thiazideproduced uric acid elevation harmful? Analysis of data from the Hypertension Detection and Follow-up Program. Arch Intern Med 1987;147:645-9.
33. Wordsworth BP, Mowat AG. Rapid development of gouty tophi after diuretic therapy. J Rheumatol 1985;12:376-7.
34. Hutcheon DE, Leonard G. Diuretic and antihypertensive actions of furosemide. J Clin Pharmacol J New Drugs 1967;7:26-33.
35. Heffeman AG. Serum enzymes and uric acid during treatment with amiloride. Lancet 1968;1:361.
36. Homeida M, Roberts CJ, Dombey SL. A single dose comparison of piretanide and bumetanide in congestive cardiac failure. Br J Clin Pharmacol 1979;8:173-8.
37. Konecke LL. Clinical trial of bumetanide versus furosemide in patients with congestive heart failure. J Clin Pharmacol 1981;21:688-90.
38. Marsh JD, Nesto R, Glynn MA, Smith TW. Comparison of intravenous piretanide and furosemide in patients with congestive heart failure. J Cardiovasc Pharmacol 1982;4:949-54.
39. Herchuelz A, Deger F, Douchamps J, Ducarne H, Broekhuysen J. Comparative pharmacodynamics of torasemide and furosemide in patients with oedema. Arzneimittelforschung 1988;38:180-3.
40. Poulsen L, Friberg M, Noer I, Krusell L, Pedersen OL. Comparison of indapamide and hydrochlorothiazide plus amiloride as a third drug in the treatment of arterial hypertension. Cardiovasc Drugs Ther 1989;3:141-4.
41. Friedel HA, Buckley MM. Torasemide. A review of its pharmacological properties and therapeutic potential. Drugs 1991;41:81-103.
42. Greenberg A. Diuretic complications. Am J Med Sci 2000;319:10-24.
43. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989;3:457-61.
44. Schrijver G, Weinberger MH. Hydrochlorothiazide and spironolactone in hypertension. Clin Pharmacol Ther 1979;25:33-42.
45. Zweifler AJ, Thompson GR. Correction of thiazide hyperuricemia by potassium chloride and ammonium chloride. Arthritis Rheum 1965;8:1134-44.
46. Bagatin J, Sardelic S, Pivac N, et al. Comparison of chlorthalidone, propranolol and bopindolol in six-month treatment of arterial hypertension. Int J Clin Pharmacol Res 1998;18:73-8.
47. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997;50:953-9.
48. Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995;49:121-42.
49. Roberts CJ, Marshall AJ, Heaton S, Barritt DW. Comparison of natriuretic, uricosuric, and antihypertensive properties of tienilic acid, bendrofluazide, and spironolactone. Br Med J 1979;1:224-6.
50. Smith JW, Clements P. Renal function during therapy in patients with congestive cardiac failure. Ticrynafen vs. hydrochlorothiazide. Nephron 1979;23(Suppl 1):41-5.
51. Kosman ME. Evaluation of a new uricosuric diuretic-ticrynafen. J Am Med Assoc 1979;242:2876-8.
52. Beg MA, Ragland R. Safety of tienilic acid. Postgrad Med J 1979;55(Suppl 3):127-32.
53. Beg MA, Zuccarello W, Donikian MA, Ragland R, Ziv DS. Renal function during ticrynafen therapy. Nephron 1979;23:64-6.
54. Johnson MW, Mitch WE. The risks of asymptomatic hyperuricaemia and the use of uricosuric diuretics. Drugs 1981;21:220-5.
55. Yu T, Berger L, Sarkozi L, Kaung C. Effects of diuretics on urate and calcium excretion. Arch Intern Med 1981;141:915-9.
56. Leary WP, Reyes AJ. Angiotensin I converting enzyme inhibitors and the renal excretion of urate. Cardiovasc Drugs Ther 1987;1:29-38.
57. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with thiazide-induced hyperuricemia [published erratum appears in Kidney Int 2000 Jan; 57(1):370]. Kidney Int 1999;56:1879-85.
58. Minghelli G, Seydoux C, Goy JJ, Bumier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268-71.
59. Elisaf M, Tsimichodimos V, Bairaktari E, Siamopoulos KC. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia. J Cardiovasc Pharmacol 1999;34:60-3.
60. Pedersen OL, Mikkelsen E. Serum potassium and uric acid changes during treatment with timolol alone and in combination with a diuretic. Clin Pharmacol Ther 1979;26:339-43.
61. Weidmann P, Gnadinger MP, Schohn D, Riesen W, Jahn H. Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure. Eur J Clin Pharmacol 1989;36:223-7.
62. Schohn DC, Jahn HA, Maareck M. Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure [discussion 9-20]. Drugs 1993;46:113-9.
63. Sagy M, Aladjem M, Shem-Tov A, et al. The renal effects of radiocontrast administration during cardioangiography in two different groups with congenital heart disease. Eur J Pediatr 1984;141:236-9.
64. Wallace SL, Robinson H, Masi AT, Decker JL, McCarthy DJ, Yu T-F. Preliminary criteria for the classification of the acute arthritis of gout. Arthritis Rheum 1977;20:895-900.
65. Agudelo CA, Weinberger A, Schumacher HR, Turner R, Molina J. Definitive diagnosis of gout by identification of urate crystals in asymptomatic metatarsophalangeal joints. Arthritis Rheum 1979;22:559-60.
66. Virtanen KS, Halonen PI. Total heart block as a complication of gout. Cardiology 1969;54:359-63.
67. Curtiss EI, Miller TR, Shapiro LS. Pulmonic regurgitation due to valvular tophi. Circulation 1983;67:699-701.
68. Arnold MH, Preston SJ, Buchanan WW. Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs. Br J Clin Pharmacol 1988;26:4889-93.
69. Ahern MJ, Reid C, Gordon TP, McCredie M, Brooks PM, Jones M. Does colchicine work? The results of the first controlled study in acute gout. Aust N Z J Med 1987;17:301-4.
70. Emmerson BT. Regimen of indomethacin therapy in acute gouty arthritis. Br Med J 1967;2:272-4.
71. Wanasukapunt S, Lertratanakul Y, Rubinstein HM. Effect of fenoprofen calcium on acute gouty arthritis. Arthritis Rheum 1976;19:933-5.
72. Widmark PH. Piroxicam: its safety and efficacy in the treatment of acute gout. Am J Med 1982;72:63-5.
73. Bluestone RH. Safety and efficacy of piroxicam in the treatment of gout. Am J Med 1982;72:66-9.
74. Schweitz MC, Nashel DJ, Alepa FP. Ibuprofen in the treatment of acute gouty arthritis. J Am Med Assoc 1978;239:34-5.
75. Nicholls MG, Espiner EA. Indomethacin-induced azotaemia and hyperkalaemia: a case study. N Z Med J 1981;94:377-9.
76. Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal antiinflammatory drugs. N Engl J Med 1984;310:563-72.
77. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH. Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 1984;310:347-52.
78. Griffin, M.R., Piper, J.M., Daugherty, J., Snowden, M., Ray, W.A., Nonsteroidal anti-inflammatory drug use and increased risk for peptic ulcer disease in elderly persons, Ann Intern Med 1991;114:257-263.
79. Findling JW, Beckstrom D, Rawsthorne L, Kozin F, Itskovitz H. Indomethacin-induced hyperkalemia in three patients with gouty arthritis. J Am Med Assoc 1980;244:1127-8.
80. Unsworth J, Sturman S, Lunec J, Blake DR. Renal impairment associated with non-steroidal anti-inflammatory drugs. Ann Rheum Dis 1987;46:233-6.
81. Chen CY, Chen CS. Stereoselective disposition of ibuprofen in patients with compromised renal haemodynamics. Br J Clin Pharmacol 1995;40:67-72.
82. Page J, Henry D. Consumption of NSAIDs and the development of congestive heart failure in elderly patients. Arch Intern Med 2000;160:777-84.
83. Heerdink ER, Leufkens HG, Herings RM, Ottervanger JP, Stricker BH, Bakker A. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med 1998;158:1108-12.
84. Poe, T.E., Scott, R.B., Keith, J.F., Jr. Interaction of indomethacin with furosemide, J Fam Pract 1983;16(610):4-6.
85. Hall D, Zeitler H, Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in severe heart failure. J Am Coll Cardiol 1992;20:1549-55.
86. Mitchell JA, Akarasereenont P, Thiemermann C, Flower RJ, Vane JR. Selectivity of nonsteroidal antiinflammatory drugs as inhibitors of constitutive and inducible cyclooxygenase. Proc Natl Acad Sci USA 1993;90:11693-7.
87. Karim A, Tolbert DS, Hunt TL, Hubbard RC, Harper KM, Geis GS. Celecoxib, a specific COX-2 inhibitor, has no significant effect on methotrexate pharmacokinetics in patients with rheumatoid arthritis. J Rheumatol 1999;26:2539-43.
88. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999;354:2106-11.
89. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. J Am Med Assoc 1999;282:1918-21.
90. Davies NM, McLachlan AJ, Day RO, Williams KM. Clinical pharmacokinetics and pharmacodynamics of celecoxib: a selective cyclo-oxygenase-2 inhibitor. Clin Pharmacokinet 2000;38:225-42.
91. Clemett D, Goa KL. Celecoxib: a review of its use in osteo-arthritis, rheumatoid arthritis and acute pain. Drugs 2000;59:957-80.
92. Whelton A, Schulman G, Wallemark C, et al. Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000;160:1465-70.
93. Swan SK, Rudy DW, Lasseter KC, et al. Effect of cyclooxygenase-2 inhibition on renal function in elderly persons receiving a low-salt diet. A randomized, controlled trial. Ann Intern Med 2000;133:1-9.
94. Rossat J, Maillard M, Nussberger J, Brunner HR, Bumier M. Renal effects of selective cyclooxygenase-2 inhibition in normotensive salt-depleted subjects. Clin Pharmacol Ther 1999;66:76-84.
95. Muscara MN, Vergnolle N, Lovren F, et al. Selective cyclooxygenase-2 inhibition with celecoxib elevates blood pressure and promotes leukocyte adherence. Br J Pharmacol 2000;129:1423-30.
96. Perazella MA, Eras J. Are selective COX-2 inhibitors nephrotoxic? Am J Kidney Dis 2000;35:937-40.
97. Spilberg I, Mandell B, Mehta J, Simchowitz L, Rosenberg D. Mechanism of action of colchicine in acute urate crystal-induced arthritis. J Clin Invest 1979;64:775-80.
98. Yü TF, Gutman AB. Efficacy of colchicine prophylaxis in gout: prevention of recurrent gouty arthritis over a mean period of five years in 208 gouty subjects. Ann Intern Med 1961;55:179-92.
99. Emmerson BT. The management of gout. N Engl J Med 1996;334:445-51.
100. Arellano F, Sacristan JA. Allopurinol hypersensitivity syndrome: a review. Ann Pharmacother 1993;27:337-43.
101. Young JL, Boswell RB, Nies AS. Severe allopurinol hypersensitivity. Association with thiazides and prior renal compromise. Arch Intern Med 1974;134:553-8.
102. Lupton GP, Odom RB. The allopurinol hypersensitivity syndrome. J Am Acad Dermatol 1979;1:365-74.
103. Bishop C, Rand R, Talbott JH. Effect of benemid (p-[di-n-propylsulfamyl]-benzoic acid) on uric acid metabolism in one normal and one gouty subject. J Clin Invest 1951;30:889-95.
104. Dayton PG, Perel JM. The metabolism of probenecid in man. Ann N Y Acad Sci 1971;179:399-402.
105. Dieterle W, Faigle JW, Mory H, Richter WJ, Theobald W. Biotransformation and pharmacokinetics of sulfinpyrazone (Anturan) in man. Eur J Clin Pharmacol 1975;9:135-45.
106. Cameron JS, Simmonds HA. Use and abuse of allopurinol. Br Med J 1987;294:1504-9.